QualityStocks.net News – Human Genome Sciences, Inc. (HGSI) Reports Progress With Several Late-Stage Products

We would like to highlight Human Genome Sciences, Inc. (NASDAQ: HGSI). The company is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. All three of these products are progressing toward commercialization. HGS also has a portfolio of drugs in earlier stages of development, led by its TRAIL receptor antibodies in mid-stage development for cancer, and substantial financial rights to three drugs in the GlaxoSmithKline (GSK) clinical pipeline.

In the Company’s recent news,

Ahead of an investors meeting in New York Wednesday, Rockville-based Human Genome Sciences reported significant progress for three late-stage products. The company said the drug Albuferon for hepatitis C and LymphoStat-B for lupus are on track for potential launch in 2010.

Also on the list is Abthrax for inhalation anthrax treatment. It is on track to begin delivery this fall. Human Genome also has an agreement with Glaxo Smith Kline to advance darapladib to Phase 3 testing for the treatment of atherosclerosis. Human Genome Sciences also said it and Glaxo Smith Kline have agreed to initiate a Phase 2 trial of LymphoStat-B for use in the treatment of multiple sclerosis.

“In June 2006, the U.S. Government exercised its option to purchase 20,000 doses of ABthrax for the Strategic National Stockpile,” the company said in a statement. “The purchase award was made under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Stockpile. HGS expects to receive $165 million in revenue from the award. In addition, there is potential for future orders for ABthrax from the U.S. Government or from other governments friendly to the U.S.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.